baber/WOPTO huggingface dataset:
Patent NZ-554348-A (NZ)
Title: Use of an anti-atherothrombotic compound in obtaining medicaments intended for the treatment of vascular disorders
Inventor: FRATACCI MARIE-DOMINIQUE
Filed: 2007-04-05
Abstract: Disclosed is the use of 3-{6-[(4-chlorophenylsulphonyl)amino]-1-methyl-5,6,7,8-tetrahydronaphth-1-yl}propionic acid of formula (I) in the form of an optical isomer or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of vascular disorders in patients having had a previous cerebral vascular accident.
Patent NZ-554485-A (NZ)
Title: Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
Inventor: ZENG DEWAN
IPC: A61K31/522
Filed: 2005-10-14
Abstract: Disclosed is the use of the A2B receptor antagonist 3-ethyl-1-propyl-8-{1-[(3-trifluoromethylphenyl)methyl]pyrazol-4-yl} -1,3,7-trihydropurine-2,6-dione for the treatment of pulmonary fibrosis or chronic obstructive pulmonary disorder (COPD).
Patent NZ-567223-A (NZ)
Title: Dispersing agents in composites
Inventor: MOAD GRAEME
IPC: B29C48/44
Filed: 2006-09-18
Abstract: Disclosed is a composition comprising (a) a synthetic polymer, (b) a talc as a filler, wherein the talc particles have a mean particle size of from 0.4 to 25 microns and are present in an amount of from 0.1 to 10 percent based on the weight of component (a) and (c) a dispersing agent which is based on a non-ionic surfactant or an amphiphilic statistical, block or comb copolymer; provided that when the synthetic polymer (a) is a polyamide, this is present in an amount of less than 55 percent based on the weight of (a), (b) and (c). Also disclosed is a process to prepare said composition and the use a said dispersing agent (c) to disperse said filler (b) into said polymer (a).
Patent NZ-569393-A (NZ)
Title: Prodrug carbonates of fenicol antibiotics
Inventor: GLINKA TOMASZ W
IPC: C07D213/40
Filed: 2006-12-20
Abstract: Disclosed herein is a fenicol carbonate compound of formula I, wherein the substituents are as defined with in the specification, processes for their preparation, compositions comprising said compounds. The present carbonate fenicol compounds have improved solubility and reduced viscosity in suitable solvent carriers.
Patent NZ-571969-A (NZ)
Title: 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
Inventor: CHARRIER JEAN-DAMIEN
IPC: C07D475/00
Filed: 2007-04-12
Abstract: Disclosed is a compound of formula I e.g. 4-((R)-5-cyclopentyl-4-ethyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-ylamino)-3- methoxy-N-(1-methylpiperidin-4-yl)benzamide or a pharmaceutically acceptable salt thereof, wherein Ring A is a triazole or imidazole ring; X1 is -NR8-; R1 is H, aliphatic, cycloaliphatic, aryl, heteroaryl, or heterocyclyl; each R2 and R3 is independently H, aliphatic, or cycloaliphatic; R4 is H, aliphatic, or cycloaliphatic; R8 is H, aliphatic, cycloaliphatic, -C(O)R, -C(O)OR, or -C(O)NRR' for treating melanoma, myeloma, leukemia, lymphoma, neuroblastoma, or a cancer selected from colon, breast, gastric, ovarian, cervical, lung, central nervous system (CNS), renal, prostate, bladder, or pancreatic.
Patent NZ-572597-A (NZ)
Title: Ribless Umbrella
Inventor: GATES GRACE
IPC: A45B11/00
Filed: 2008-11-05
Abstract: An umbrella 1 includes a flexible canopy 2, a ring frame 3 attached around the outer edge of the canopy and a pole 5 with a canopy bearing surface 4 over which central portion of the canopy is tensioned and supported. The canopy is restrained and stretched and tensioned in place over the bearing surface by cord loops 8 having their ends 11 attached to spaced apart points around the frame and looping around a ring that is located around the pole 5.
Patent NZ-572920-A (NZ)
Title: Self-boring bonding anchor
Inventor: BAYERL MICHAEL
IPC: E21D20/00
Filed: 2008-11-19
Abstract: A self-boring bonding anchor for mining and tunnel construction is disclosed. An anchor tube (11) has a boring head (13) at a first end and a free second end (14). An inner tube (15) with an internal space (16) to accommodate a squeezable substance (30) is provided in the anchor tube, with an intermediate space (17) extending between the anchor tube and the inner tube. An axial opening (18) that communicates with the internal space in the inner tube is provided in the region of the free second end. At least one radial opening (19) is also provided in the region of the second end, with the radial opening being in connection with at least one outlet opening (20) in the region of the boring head via the intermediate space. For wet boring applications water may be supplied through the radial opening(s) to the outlet opening(s).
Patent NZ-574187-A (NZ)
Title: Article of luggage comprising a shape defining framework and a telescopically incorporated towing handle
Inventor: SELVI SEDAT
IPC: A45C5/03
Filed: 2007-07-13
Abstract: A suitcase (1) comprising a shape defining framework (2) is disclosed. The framework (2) is formed from a plurality of elongated members (5, 6, 7, 8 and 9) that are interconnected in their end regions by end pieces (18 and 30). The framework (2) comprises the lid section (21) and base section (3). The length of the suitcase (1) is defined by two elongated members (6) of the base section (3) with which a towing handle (10) is telescopically engageable.
Patent NZ-574599-A (NZ)
Title: System and method for performing motion capture and image reconstruction
Inventor: COTTER TIM S
IPC: G06T7/20
Filed: 2007-07-31
Abstract: A computer-implemented method implemented within a motion capture system for performing surface reconstruction of a subject having a three dimensional capture volume from multiple-range data sets is disclosed. The method comprises creating a scalar field for the three-dimensional (3-D) capture volume of the subject; generating a surface mesh for the scalar field; retaining a first set of vertices based on relative positioning of the vertices to range values for a specified number of cameras and removing a second set of vertices of the surface mesh based on relative positioning of the vertices to the range values for the cameras or a determination as to whether the vertices fall into a region of no data of a specified number of cameras; and storing the first set of vertices for use in subsequent reconstruction of the motion of the subject.
Patent NZ-583517-A (NZ)
Title: Method of making flush door skins and assembled doors, and universal master boards for the same
Inventor: WYSOCK GREGORY J
IPC: E06B3/70
Filed: 2010-02-23
Abstract: Disclosed is a method of converting universal master boards into flush door skins having different assortments of simulated wood grain patterns. The method includes the steps of providing a plurality of universal master boards which each have an expansive surface. Each expansive surface has a graphic design of at least first depressions and second depressions in at least first and second surface regions, respectively. The first depressions are substantially parallel to one another and substantially aligned in a first direction to simulate a first wood grain pattern in the first surface region. The second depressions are substantially parallel to one another and substantially aligned in a second direction that is different than the first direction to simulate a second wood grain pattern in the second surface region. The plurality of universal master boards including at least first and second universal master boards. The method includes the steps of cutting the first universal master board at a first location to form a first flush door skin having a first exterior surface with a first assortment of simulated wood grains comprising at least one pattern selected from the group consisting of the simulated first wood grain pattern and the simulated second wood grain pattern. The method includes cutting the second universal master board at a second location which does not correspond to the first location to form a second flush door skin having a second exterior surface with a second assortment of simulated wood grains comprising at least one pattern selected from the group consisting of the simulated first wood grain pattern and the simulated second wood grain pattern. The second assortment of simulated wood grains is different from the first assortment of simulated wood grains.
Patent NZ-597608-A (NZ)
Title: Redox method for capture of total gaseous mercury by wet fgd
Inventor: GHORISHI S BEHROOZ
IPC: B01D47/00
Filed: 2010-07-15
Abstract: 597608 Disclosed is a method for removing elemental mercury from flue gas in wet scrubber comprising the steps of: providing a wet scrubber having a scrubber slurry; providing a flue gas comprising a sulfur dioxide (SO2), a oxidized mercury, and an elemental mercury; enabling the flue gas to pass through the scrubber; introducing a mercury oxidizer into the scrubber slurry, and oxidizing the elemental mercury with the mercury oxidizer at a gas-liquid interface of the flue gas and the scrubber slurry within the wet scrubber; and introducing a promoter into the scrubber slurry, wherein the promoter acts as an oxidizing agent for sulfite oxidation but not for elemental mercury oxidation.
Patent NZ-598121-A (NZ)
Title: Nitroimidazooxazines and their uses in anti-tubercular therapy
Inventor: DENNY WILLIAM ALEXANDER
IPC: A61K31/5365
Filed: 2010-07-30
Abstract: 598121 Disclosed herein is a compound of formula I, wherein the variables are defined in the specification, and the use thereof in the treatment of microbial infection. Embodiments of the compound include: (6S)-6-{ [2'-chloro-4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methoxy} -2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, (6S)-2-nitro-6-({ 4-[4-(trifluoromethoxy)benzyl]benzyl} oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, and (6S)-2-Nitro-6-[(6-{ [4-(trifluoromethoxy)phenyl]ethynyl} -3-pyridinyl)methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine.
Patent NZ-598732-A (NZ)
Title: Dosage regimen for administering a cd19xcd3 bispecific antibody
Inventor: BAEUERLE PATRICK
IPC: A61K39/395
Filed: 2010-10-27
Abstract: Disclosed is an in vitro method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells determining in a sample from said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Further disclosed is the use of a CD19xCD3 bispecific antibody for the preparation of a pharmaceutical composition for treating malignant CD19 positive lymphocytes and ameliorating and/or preventing an adverse effect mediated by the administration of a CD19xCD3 bispecific antibody in a human patient identified as having a B : T cell ratio of about 1:5 or lower, wherein said B : T cell ratio can be determined by the following steps: a) determining the total B cells in a peripheral blood sample from said patient; b) determining the total T cells in a peripheral blood sample from said patient; c) calculating the ratio of the total B cells of step a) and the total T cells of step b) in order to obtain a B : T cell ratio; d) wherein said composition is formulated for administration in a first dose of a CD19xCD3 bispecific antibody for a first period of time to said human patient; and e) wherein said composition is formulated for consecutive administration in a second dose of said antibody for a second period of time to said human patient; wherein said first period of time is between 3 days and 10 days, and said second period of time is between 3 days and 10 days.
Patent NZ-603173-A (NZ)
Title: Manufacturing of active-free granules and tablets comprising the same
Inventor: MOHAMMAD HASSAN
IPC: A61K9/20
Filed: 2011-05-10
Abstract: Disclosed herein is a method of manufacturing an oral prolonged release pharmaceutical composition comprising at least the steps of: (a) producing granules comprising at least one prolonged release material selected from the group comprising hydrophobic or hydrophilic polymers, protein-derived material, gums, waxes, oils, fatty acids or fatty alcohols, wherein the granules do not comprise a pharmaceutically active agent; (b) selecting granules of step (a) of substantially uniform size; (c) blending said granules of step (a) or step (b) with at least two pharmaceutically active agents, wherein the first pharmaceutically active agent is an opioid agonist and the second pharmaceutically active agent is an opioid antagonist, and wherein the at least two pharmaceutically active agents are provided as such that they are not comprised within granules; (d) compressing said blended granules of step (c) to obtain an oral prolonged release pharmaceutical composition in the form of a tablet, wherein the opioid agonist is selected from oxycodone, hydromorphone, hydrocodone, tramadol or oxymorphone or their pharmaceutically acceptable salts, hydrates and solvates thereof and wherein the opioid antagonist is selected from naloxone, naltrexone or nalmephene or their pharmaceutically acceptable salts, hydrates and solvates.
Patent NZ-608113-A (NZ)
Title: Dilution-stable cement grinding additive composition
Inventor: JARDINE LESLIE A
IPC: C08L5/00
Filed: 2011-09-12
Abstract: This disclosure relates to cement grinding additive compositions that comprise of at least one amine cement grinding additive, tri-iso-butylphosphate (in an amount of 0.05 to 5.0 percent, a biopolymer polysaccharide gum in an amount of 0.05 to 1.0 percent and water in an amount of 35 to 9 percent. The amine cement grinding additive is selected from triisopropanolamine, diethanolisopropanolamine and diisopropanolethanolamine and the biopolymer polysaccharide gum is selected from diutan, welan and xanthan gum. The composition may optionally include further additives. The composition allows the defoamer (the phosphate) to be uniformly dispersed while retaining storage stability whereby, if said cement grinding additive composition were placed in a vessel, said tri-iso-butylphosphate displays uniformity of tri-iso-butylphosphate dispersal within the entire volume of the composition wherein the average concentrations of tri-iso-butylphosphate between the top and bottom one-third fractions of the vessel should not differ by more than 20%, when stored at 100 degrees Fahrenheit for 10 days. The disclosure also relates to methods of manufacturing cement using the additive.
Patent NZ-609607-A (NZ)
Title: Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
Inventor: RODRIGUEZ MOSES
IPC: C07K16/18
Filed: 2011-10-19
Abstract: Disclosed is an isolated human IgM antibody or fragment thereof which specifically binds neurons and protects neurons from cell death and which does not promote remyelination, wherein the antibody or fragment comprises CDR Sequences of: HCDR1 GFTFSTYA (SEQ ID NO: 37); HCDR2 INVGGVTT (SEQ ID NO:38); HCDR3 VRRSGPDRNSSPADF (SEQ ID NO:39); LCDR1 QGIG (SEQ ID NO: 40); LCDR2 TTS (SEQ ID NO:41); LCDR3 QKYNSAPRT (SEQ ID NO: 42); for use in treating or ameliorating diseases or conditions in mammals where nerves are compromised, injured or damaged or are at risk thereof. Also disclosed is the use of said antibody in the manufacture of a medicament for targeting and determining neuron injury, death or damage, or cells at risk thereof, in the CNS in a mammal.
Patent NZ-613569-A (NZ)
Title: Forms of rifaximin and uses thereof
Inventor: PARENT STEPHAN
IPC: C07D498/22
Filed: 2012-02-10
Abstract: Disclosed is crystalline rifaximin polymorphic form Mu having an X-ray powder diffraction comprising peaks, in terms of 2θ (± 0.2), at 4.72, 4.79, 7.84, 8.11, 8.36, 8.55, 8.70, 9.60, and 12.54. Also disclosed is a process for the preparation of polymorphic form Mu as defined above by hydrating rifaximin polymorph Form theta (as described herein) to between 44% and 75% relative humidity (RH). Also disclosed is a method of producing rifaximin polymorph Form Mu comprising fast evaporation of rifaximin from a 1:1 (v/v) ethanol/heptane solution at room temperature, such as by evaporation in a fume hood.
Patent NZ-616780-A (NZ)
Title: A method for the treatment of a solid tumour
Inventor: HAWKETT BRIAN STANLEY
IPC: B82Y5/00
Filed: 2012-04-20
Abstract: Disclosed herein is the use of two separate formulations of a particulate material, and a cellular toxin, effective to penetrate a solid tumour and induce cytotoxicity, in the manufacture of a medicament for the treatment of a solid tumour, wherein said particulate material is in the form of a dispersion in a liquid carrier, the particulate material being maintained in the dispersed state by a steric stabiliser; wherein said steric stabiliser comprises an anchoring portion and a steric stabilising polymeric segment, wherein the anchoring portion is different from the steric stabilising polymeric segment; and wherein the anchoring portion has an affinity towards the surface of the particulate material and secures the stabiliser to the particulate material.
Patent NZ-711754-A (NZ)
Title: Pharmaceutical compositions for the treatment of helicobacter pylori
Inventor: FATHI REZA
IPC: A61P31/04
Filed: 2014-02-12
Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. or the prevention of recurrence of disorders associated with infection by pylori.
Patent NZ-716779-A (NZ)
Title: Nutritional composition having lipophilic compounds with improved solubility and bioavailability
Inventor: VURMA MUSTAFA
IPC: A23C9/20
Filed: 2014-08-28
Abstract: Disclosed herein is a nutritional composition having at least one protein, at least one fat, and at least one lipophilic compound, the composition comprising at least one assembly comprising at least one hydrophobic protein, monoglycerides and diglycerides (”MDG”) and at least one lipophilic compound, wherein at least 1% of the total MDG in the nutritional composition remains in the aqueous phase after centrifugation at 100,000 x g for 1 hour at 20°C.
Patent NZ-723391-A (NZ)
Title: Medication requisition fulfillment system and method
Inventor: SCHNEIDER DENNIS I
IPC: G16H10/60
Filed: 2013-03-14
Abstract: The present invention generally relates to an improved system and associated method for fulfillment of a medication requisition to be dispensed by a patient care provider for administration to a patient. In particular, the present invention relates to a pharmacy medication management system for use at a pharmacy, comprising: a pharmacy work station at the pharmacy that includes a processor that executes machine-readable instructions stored in a memory to configure the pharmacy work station to: generate a medication requisition, in an automated or partially automated manner, for a contained medication unit of a compounded sterile product based on an order of the contained medication unit of the compounded sterile product prescribed by a physician, execute requisition fulfillment logic to provide decision data to a user of the pharmacy workstation for use in selecting one of a plurality of remote fulfillment sites to which the medication requisition is to be sent, wherein the decision data is based at least in part on cost data or timing data received at the pharmacy work station from each of the plurality of remote fulfillment sites, and execute a requisition router that communicates the medication requisition to a selected remote fulfillment site that is selected from the plurality of remote fulfillment sites, wherein the remote fulfillment site comprises a work station to prepare and present a work flow that is specific to the medication requisition to a user of the work station including a sequence of steps to prepare the contained medication unit of the compounded sterile product corresponding to the medication requisition based on the work flow and record, using data collection tools, medication requisition metadata comprising barcode scans of products and images related to preparation of the contained medication unit of the compounded sterile product documenting preparation of the contained medication unit of the compounded sterile product in accordance with the work flow; a medication requisition database in operative communication with the pharmacy work station that receives and stores the medication requisition metadata regarding fulfillment of the medication requisition at a selected one of the plurality of remote fulfillment sites; wherein the pharmacy work station associates the medication requisition metadata stored in the medication requisition database with the contained medication unit of the compounded sterile product that is physically obtained at the pharmacy work station at the pharmacy.
Patent NZ-726571-A (NZ)
Title: Product application device
Inventor: SHORLAND SIMON T
IPC: A45D40/26
Filed: 2015-04-23
Abstract: A device and method for drying a substance applied to a surface by a roller ball, as it is being applied to the surface. The device is designed to apply a form of energy including air movement, heat, or light and can be designed to apply combinations of energy forms. The energy form is applied to the surface during or after the substance has been applied to the surface. A design for the shape of the enclosure (11) and features included in the enclosure (11) for the device are disclosed which enhances the drying efficiency.
Patent NZ-737173-A (NZ)
Title: Reinforced masonry wall
Inventor: VAN DER LEEST MARTIN CHRISTIAAN
IPC: E04G23/02
Filed: 2016-04-20
Abstract: A masonry wall is built from individual units laid in and bound together by mortar. Although masonry is generally a highly durable form of construction and masonry has high compressive strength under vertical loads, it has low tensile strength (against twisting or stretching) unless reinforced. Unreinforced masonry buildings are highly vulnerable to damage during earthquakes, due to their high mass, limited ductility and low tensile strength. Disclosed herein is a wall of a building, wherein: the wall is a masonry wall built from individual units laid in and bound together by mortar; a plurality of passageways is provided in said wall, the passageways each being elongated in a longitudinal direction; at least one reinforcement member is provided in each of said passageways, the reinforcement members being elongated in the longitudinal direction of the passageways; the reinforcement members in the passageways are each embedded in an adhesive substance, the adhesive substance being bonded to each of the reinforcement members and to an inner surface of the passageway in which the reinforcement member is provided; and said adhesive substance has an elongation at break of at least 40% (DIN 53504 2009 edition) and a hardness at room temperature of at most 100 Shore A. Also disclosed herein is a masonry wall of a building built from individual units laid in and bound together by mortar, the wall further comprising a stabilizing layer covering a vertical surface of said wall, said stabilizing layer being composed of a matrix material and fibres embedded in the matrix material, the matrix material adhering to the vertical surface of the wall, wherein the matrix material has an elongation at break of at least 250% at 24°C (ASTM D412-06a(2013)) and a hardness of at most 120 Shore A or at most 60 Shore D (ASTM D2240-05(2010)). The walls can accommodate relatively large deformations, and thereby have increased resistance against earthquakes.